FULC · Fulcrum Therapeutics, Inc.
$3.84
-0.01 (-0.26%)
At close · Aug 21
Market Cap
$292.60M
Shares
76.30M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.85
Open$3.88
Day$3.81–3.91
52W close$3.14–14.60
Avg vol 30d1.7M
Short int6.6M · 8.7% float · 4.5d
Short vol48%
Last earningsApr 27, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 30
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 30, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−49%
below
Price vs 50-day avg
+4%
above
RSI (14)
53
neutral
MACD trend
Positive
52-week position
6%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+2%
trailing
6-month return
−54%
trailing
YTD return
−66%
this year
Relative strength
−65%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $8 — 200d above 50d
Institutional flow
Distributing
-9% holders QoQ · +29 funds added
Insider flow
Accumulating
Net +$1.4M over 90 days · 50% sells
Short interest
Falling
8.69% of float · ▼ -4.0% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
154 holders — mid 3-yr range
Squeeze score
72
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
−638%
Y/Y
Free cash flow
$-60.4M
Balance sheet
$197.5M
net cash
Quant / Vol
risk profile
Volatility
98%
annualized · 1-yr
Max drawdown
−78%
past year
ATR
4.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−49%
Bearish
Price vs 50-day avg
+4%
Bullish
RSI (14)
53
Neutral
MACD trend
Positive
Bullish
52-week position
6%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $8 — 200d above 50d
Institutional flow
Distributing
-9% holders QoQ · +29 funds added
Insider flow
Accumulating
Net +$1.4M over 90 days · 50% sells
Short interest
Falling
8.69% of float · ▼ -4.0% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
154 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $4 · 6%
Range high $15
vs 200-day avg -49%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FULC
this stock
Fulcrum Therapeutics, Inc.
|
$292.60M | -66.0% | -100.0% | — | 8.7% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FULC | +3.8% | +2.4% | -54.1% | +7.5% | -66.0% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +5.7% | -0.9% | -65.2% | +5.5% | -77.8% |
Key facts
CIK
1680581
CUSIP
359616109
13F (30d)
148 filings
144 filers
Visit website
Investor relations